ICICI Securities: Pharma Sector 2021 Outlook - Valuation Rerating To Sustain
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
We remain positive on the pharma sector for next year as we expect growth in India formulations to revive to 10-11%, cost control measures undertaken during the pandemic to aid profitability, and positive growth in U.S. sales on a corrected base coupled with normalised price erosion.
Pharma companies under our coverage witnessed an average 58% increase in stock prices over the past one year largely due to improved profitability and valuation rerating given growth visibility.
U.S. Food and Drug Administration inspections have been restricted in CY20 due to the pandemic and would resume once the Covid-19 situation normalises.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.